Novartis exercised an option to acquire full global rights to Sironax’s brain delivery platform for $125 million, while Sironax retains rights to develop selected assets using the technology. The deal is designed to improve delivery of therapeutic compounds across the blood-brain barrier, a capability that Novartis views as strategically valuable for CNS and neurodegenerative programs. Sironax said the proceeds will advance three clinical-stage programs plus early-stage candidates, and that it is also continuing development of a next-generation delivery platform using different modules than those acquired. The structure keeps Sironax involved on specific programs while transferring the underlying platform to Novartis. For the market, the transaction reflects continued M&A appetite around delivery technologies that can expand modality feasibility in the CNS—particularly as large pharma looks for differentiated levers amid pipeline setbacks.